Submission of the IND Amendment enables the commencement of a Diabetic Macular Edema (DME)/Diabetic Nephropathy (DN) Phase 2b clinical trial to be undertaken by the DRCR Retina Network, which is ...
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025 Amendment should benefit both parties from a cost ...
SAN JOSE, Calif., Feb. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback